Evaluation of oral herpes simplex virus shedding among solid organ transplant recipients: A pilot study.
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
revised:
21
06
2024
received:
18
06
2024
accepted:
24
06
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
16
7
2024
Statut:
aheadofprint
Résumé
Herpes simplex viruses (HSVs) frequently reactivate during immunosuppression and may be a risk factor for adverse outcomes after solid organ transplant (SOT). While suppressive antiviral therapy reduces the risk of symptomatic HSV reactivation, the kinetics of asymptomatic viral shedding with chronic immunosuppression after transplant are not well understood. We report the characteristics of oral HSV shedding among 15 HSV-1 seropositive SOT recipients (n = 8 liver, n = 7 kidney, median age 58.5 years, median 20 months post-transplant) who were not taking daily antiviral suppressive therapy. Participants self-collected oral swabs three times daily for 6 weeks for HSV quantification and recorded the presence of oral symptoms or lesions in a diary. Sample collection adherence was high (median 122 swabs/person, range: 85.7%-101.6% of expected swabs). Most participants (n = 12, 80%) experienced at least one shedding episode, with a median shedding rate of 8.9% (range: 0%-33.6%). There were 32 total shedding episodes, 24 (75%) of which occurred without symptoms or lesions. For episodes of known duration, the median length was 21.8 hrs (interquartile range: 10.8-46.1 hrs). Most shedding episodes (78.1%) lasted >12 hrs, suggesting that twice-daily sampling may be sufficient to detect most episodes. These data show that self-collection of oral swabs is feasible for patients who have undergone SOTs and can provide insight into the frequency of oral HSV reactivation, which can be used to design future studies in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Herpes simplex viruses (HSVs) frequently reactivate during immunosuppression and may be a risk factor for adverse outcomes after solid organ transplant (SOT). While suppressive antiviral therapy reduces the risk of symptomatic HSV reactivation, the kinetics of asymptomatic viral shedding with chronic immunosuppression after transplant are not well understood. We report the characteristics of oral HSV shedding among 15 HSV-1 seropositive SOT recipients (n = 8 liver, n = 7 kidney, median age 58.5 years, median 20 months post-transplant) who were not taking daily antiviral suppressive therapy.
METHODS
METHODS
Participants self-collected oral swabs three times daily for 6 weeks for HSV quantification and recorded the presence of oral symptoms or lesions in a diary.
RESULTS
RESULTS
Sample collection adherence was high (median 122 swabs/person, range: 85.7%-101.6% of expected swabs). Most participants (n = 12, 80%) experienced at least one shedding episode, with a median shedding rate of 8.9% (range: 0%-33.6%). There were 32 total shedding episodes, 24 (75%) of which occurred without symptoms or lesions. For episodes of known duration, the median length was 21.8 hrs (interquartile range: 10.8-46.1 hrs).
CONCLUSION
CONCLUSIONS
Most shedding episodes (78.1%) lasted >12 hrs, suggesting that twice-daily sampling may be sufficient to detect most episodes. These data show that self-collection of oral swabs is feasible for patients who have undergone SOTs and can provide insight into the frequency of oral HSV reactivation, which can be used to design future studies in this population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14335Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : T32 AI 007044
Organisme : National Institute of Allergy and Infectious Diseases
ID : K-23AI097234
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
McQuillan G, Kruszon‐Moran D, Paulose‐Ram R, Flagg EW. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. NCHS Data Brief. 2018;304:1‐8.
Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198(8):1141‐1149. doi:10.1086/591913
Miller CS, Danaher RJ. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(1):43‐50. doi:10.1016/j.tripleo.2007.06.011
Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV‐1 DNA in Tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005;46(1):241. doi:10.1167/iovs.04‐0614
Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis. 1977;136(4):531‐540. doi:10.1093/infdis/136.4.531
Seale L. Prevention of herpesvirus infections in renal allograft recipients by low‐dose oral acyclovir. JAMA. 1985;254(24):3435‐3438.
Lee DH, Zuckerman RA. Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13526. doi:10.1111/ctr.13526
Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G‐specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26(4):662‐667. doi:10.1128/jcm.26.4.662‐667.1988
Ryncarz AJ, Goddard J, Wald A, Huang M‐Li, Roizman B, Corey L. Development of a high‐throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol. 1999;37(6):1941‐1947. doi:10.1128/JCM.37.6.1941‐1947.1999
Jerome KR, Huang M‐Li, Wald A, Selke S, Corey L. Quantitative stability of DNA after extended storage of clinical specimens as determined by real‐time PCR. J Clin Microbiol. 2002;40(7):2609‐2611. doi:10.1128/JCM.40.7.2609‐2611.2002
Tronstein E. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV‐2 infection. JAMA. 2011;305(14):1441‐1449.
Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV‐infected adults. J Acquir Immune Defic Syndr. 2010;54(5):482‐488. doi:10.1097/QAI.0b013e3181d91322
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333(12):770‐775.
Peng T, Phasouk K, Sodroski CN, et al. Tissue‐resident‐memory CD8+ T cells bridge innate immune responses in neighboring epithelial cells to control human genital herpes. Front Immunol. 2021;12:735643. doi:10.3389/fimmu.2021.735643
Sarmento DJDeS, Tozetto‐Mendoza TR, De Souza ACMF, Maciel R, Paiao H, Lima SH, Cristelli M, Pestana JOMDeA, Braz‐Silva PH, Gallottini M Herpesviruses oral shedding and viremia in renal transplant recipients: a longitudinal study. Transpl Infect Dis. 2020;22(4):e13330. doi:10.1111/tid.13330
Miranda‐Silva W, De Molla VC, Knebel FH, et al. Oral shedding of herpes viruses and clinical outcomes in hematopoietic stem cell transplant patients. Oral Dis. 2023;29(2):815‐826. doi:10.1111/odi.14022